An adjuvant is a substance added to a vaccine or immunologic product to enhance the recipient's immune response to the active antigen. In localization, the term appears in clinical trial documents, regulatory submissions, product monographs, investigator brochures, patient information, and healthcare provider materials; it is often described alongside the antigen in vaccine composition statements and safety discussions or comparative immunogenicity sections.
Adjuvant terminology occurs in vaccine SmPCs, informed consent forms, clinical study reports, and public health translation. Translators must clearly separate the adjuvant from the antigen and excipient categories, especially when explaining adverse reactions or immunogenicity results to patients and study participants. Public-facing materials may need simplified phrasing without changing technical meaning.
A common mistake is treating an adjuvant as a preservative or excipient, or translating it as 'additive' in a way that minimizes its role. This can distort vaccine composition and safety information. In patient materials, mistranslating the adjuvant name may cause confusion with allergens or ingredients that contraindicate the vaccine. Such errors may undermine informed consent.
FDA, CE/MDR and NMPA reviewers assess the submitted wording itself. Regulatory bodies require traceable, accountable translation, and an inconsistent term can delay or fail a submission.
Angel Translation locks terms like this into a project terminology base before expert review begins, so the same source term resolves to the same target term across every document in a submission — and stays consistent in the next revision. See the 8-step AI + expert workflow.
Send us the files. Acknowledged in 4 hours, quoted in 24.
Request a Quote →Life Science solutions →